PD-1 Antibody(YA3401)
(Synonyms: Programmed cell death protein 1; CD279; CD279 antigen; hPD 1; hPD-1; hSLE1; PD 1; PD1; PDCD 1; PDCD1; PDCD1_HUMAN; Programmed cell death 1; Protein PD 1; Protein PD-1; SLEB2; Systemic lupus erythematosus susceptibility 2.)Based on 4 publication(s) in Google Scholar
PD-1 Antibody(YA3401) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PD-1.
-
Host:
Mouse
-
Isotype:
IgG
-
Application:
WB, IHC-P, ICC/IF, FC
-
Reactivity :
Human
-
Formulation:
Supplied in 1*PBS (pH7.4), 0.2% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.
-
Conjugation:
Non-conjugated
Publications Citing Use of MedChemExpress (MCE) PD-1 Antibody(YA3401)
More
Applications
| Application |
WB
WB: Western Blot
|
ICC/IF
ICC/IF: Immunocytochemistry/
Immunofluorescence |
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
FC
FC: Flow Cytometry
|
|---|---|---|---|---|
| Dilution Ratio | 1:500-1:2000 | 1:50-1:200 | 1:100-1:500 | 1:50-1:100 |
Product Details
PD-1 Antibody(YA3401) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PD-1.
-
Host Mouse
-
Clonality Monoclonal
-
Species ReactivityHuman
-
Observed Molecular WeightObserved band size: 32 kDa,47-55 kDaNote: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 32 kDa
Recombinant protein within Human PD1 aa 1-200 / 288.
Endogenous
affinity purified
Non-conjugated
Unmodified
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in 1*PBS (pH7.4), 0.2% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.
-
Concentration
Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Clin Immunol
Inhibition of neutrophil extracellular traps via the FGF19/ERK/IL-8 axis enhances immune therapy in MSS colorectal cancer. [Abstract]2026 Apr:284:110664. PMID: 41565192 -
J Leukoc Biol
Progenitor-predominant exhaustion in cytokine-induced killers reveals TIM-3 as a superior target for enhancing cytokine-induced killer cytotoxicity. [Abstract]2025 Dec 26;118(1):qiaf180. PMID: 41414757 -
Biochem Biophys Res Commun
Dihydroartemisinin restrains angiogenesis through the TNF-α pathway to enhance the efficacy of anti-PD-1 immunotherapy in breast cancer. [Abstract]2025 Aug 30:776:152171. PMID: 40527175
Verification Images
-
Western blot analysis of extracts from Jurkat(lane 2(20μg), Molt-4(lane 3(20μg), THP-1(lane 4(20μg) and K562(lane 5(20μg) using PD-1 Antibody (HY-P81169A). Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80993,1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse IgG-HRP Secondary Antibody (HY-P8004,1/10,000) was used for 1 hour at room temperature.
-
Immunohistochemical analysis of paraffin-embedded human lung cancer tissue(negative) using PD-1 Antibody(YA3401). The section was pre-treated using heat mediated antigen retrieval with Tris/EDTA buffer (pH 9.0) for 20 minutes. The tissues were probed with the primary antibody (HY-P81169A,1/100) overnight at 4℃. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with neutral balsam.
-
Immunohistochemical analysis of paraffin-embedded human tonsil tissue using PD-1 Antibody(YA3401). The section was pre-treated using heat mediated antigen retrieval with Tris/EDTA buffer (pH 9.0) for 20 minutes. The tissues were probed with the primary antibody (HY-P81169A,1/100) overnight at 4℃. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with neutral balsam.
-
Immunohistochemical analysis of paraffin-embedded human lymph node tissue using PD-1 Antibody(YA3401). The section was pre-treated using heat mediated antigen retrieval with Tris/EDTA buffer (pH 9.0) for 20 minutes. The tissues were probed with the primary antibody (HY-P81169A,1/100) overnight at 4℃. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with neutral balsam.
-
Immunohistochemical analysis of paraffin-embedded human breast cancer tissue (negative) using PD-1 Antibody(YA3401). The section was pre-treated using heat mediated antigen retrieval with Tris/EDTA buffer (pH 9.0) for 20 minutes. The tissues were probed with the primary antibody (HY-P81169A,1/100) overnight at 4℃. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with neutral balsam.
-
Immunohistochemical analysis of paraffin-embedded human lymphoma tissue using PD-1 Antibody(YA3401). The section was pre-treated using heat mediated antigen retrieval with Tris/EDTA buffer (pH 9.0) for 20 minutes. The tissues were probed with the primary antibody (HY-P81169A,1/100) overnight at 4℃. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with neutral balsam.
-
Immunohistochemical analysis of paraffin-embedded human hodgkin's lymphoma tissue using PD-1 Antibody(YA3401). The section was pre-treated using heat mediated antigen retrieval with Tris/EDTA buffer (pH 9.0) for 20 minutes. The tissues were probed with the primary antibody (HY-P81169A,1/100) overnight at 4℃. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with neutral balsam.
-
Immunohistochemical analysis of paraffin-embedded human lung adenocarcinoma tissue using PD-1 Antibody(YA3401). The section was pre-treated using heat mediated antigen retrieval with Tris/EDTA buffer (pH 9.0) for 20 minutes. The tissues were probed with the primary antibody (HY-P81169A,1/100) overnight at 4℃. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with neutral balsam.
Background
-
Function
CD279 (PD-1, PDCD1) is a classic immune checkpoint receptor primarily expressed on activated T cells, exhausted T cells, Tregs, and a subset of NK cells. By binding to PD-L1/PD-L2 and inhibiting TCR signaling, it suppresses T-cell proliferation and cytotoxic function; it serves as a key target in research concerning tumor immune escape, T-cell exhaustion, and immunotherapy.
-
Subcellular Localization
Cell membrane; Single-pass type I membrane protein
-
Subunit
Monomer. Interacts with CD274/PDCD1L1. Interacts with FBXO38; leading to ubiquitination and degradation of PDCD1 by the proteasome
-
SwissProt ID
-
Synonyms
Programmed cell death protein 1; CD279; CD279 antigen; hPD 1; hPD-1; hSLE1; PD 1; PD1; PDCD 1; PDCD1; PDCD1_HUMAN; Programmed cell death 1; Protein PD 1; Protein PD-1; SLEB2; Systemic lupus erythematosus susceptibility 2.
Documentation
-
Data Sheet (262 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
User Guide for Antibodies (1077 KB)
[1]. Fife BT, et al. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann N Y Acad Sci. 2011 Jan;1217:45-59. [Content Brief]
[2]. Xiao X, et al. ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy. Nat Commun. 2023 May 19;14(1):2859. [Content Brief]
[3]. Berger KN, et al. PD-1 pathway and its clinical application: A 20year journey after discovery of the complete human PD-1 gene. Gene. 2018 Jan 5;638:20-25. [Content Brief]
[4]. Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28;366(26):2443-54. [Content Brief]
[5]. Robert C, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014 Sep 20;384(9948):1109-17. [Content Brief]
[6]. Robert C, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015 Jan 22;372(4):320-30. [Content Brief]